Protara Therapeutics EBITDA 2011-2026 | TARA

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Protara Therapeutics

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-48.8 M	-43.3 M	-66.8 M	-47.4 M	-34.2 M	-15 M	-21.3 M	-30.2 M	-28.6 M	-20.8 M	-7.55 M	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-7.55 M	-66.8 M	-33.1 M

Quarterly EBITDA Protara Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-14 M	-	-	-	-11.8 M	-	-	-	-9.66 M	-	-7.8 M	-8.6 M	-10.8 M	-	-10.8 M	-12.7 M	-13.5 M	-	-7.99 M	-7.22 M	-10.1 M	-	-2.25 M	-1.41 M	-1.35 M	-	-4.6 M	-4.97 M	-6.33 M	-	-12.2 M	-5.91 M	-6.44 M	-	-7.08 M	-7.8 M	-6.8 M	-	-5.05 M	-4.96 M	-4.61 M	-	155 K	-2.5 M	-1.93 M	-	-1.89 M	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
155 K	-14 M	-6.87 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
Alector ALEC	-150 M	$ 2.19	-9.77 %	$ 226 M	USA
Acer Therapeutics ACER	-24.5 M	-	2.71 %	$ 14 M	USA
I-Mab IMAB	13.8 M	-	-	$ 866 M	China
Cabaletta Bio CABA	-73.2 M	$ 3.34	0.45 %	$ 3.9 M	USA
Alexion Pharmaceuticals, Inc. ALXN	3.11 B	-	-	$ 40.3 B	USA
AgeX Therapeutics AGE	-9.76 M	-	-10.17 %	$ 12.2 K	USA
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Aeglea BioTherapeutics AGLE	-242 M	-	-	$ 1.01 B	USA
Codexis CDXS	-53.6 M	$ 1.02	1.49 %	$ 74.9 M	USA
AbCellera Biologics ABCL	-199 M	$ 3.74	3.6 %	$ 1.12 B	Canada
Applied Genetic Technologies Corporation AGTC	-16.2 M	-	-	$ 26.5 M	USA
Cerus Corporation CERS	-12.4 M	$ 2.6	1.37 %	$ 480 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	-8.18 M	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
Cellectis S.A. CLLS	-131 M	$ 3.87	-0.39 %	$ 116 M	France
ARCA biopharma ABIO	-88.1 M	-	1052.0 %	$ 415 M	USA
Acorda Therapeutics ACOR	-233 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	-16.7 M	-	4.01 %	$ 150 M	Canada
CNS Pharmaceuticals CNSP	-14.9 M	$ 3.23	2.22 %	$ 1.23 M	USA
Adverum Biotechnologies ADVM	-136 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	220 M	-	-	-	Russia
AIkido Pharma AIKI	-11.4 M	-	1.93 %	$ 17.4 M	USA
Collegium Pharmaceutical COLL	64.9 M	$ 41.75	0.19 %	$ 1.32 B	USA
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
Akouos AKUS	-84.3 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	-123 M	-	-0.23 %	$ 916 M	USA
Corcept Therapeutics Incorporated CORT	45.9 M	$ 36.14	1.23 %	$ 3.75 B	USA
Allena Pharmaceuticals ALNA	-47.3 M	-	3.16 %	$ 1.9 M	USA
Amarin Corporation plc AMRN	-67.4 M	$ 13.98	1.27 %	$ 5.7 B	Irlanda
Aileron Therapeutics ALRN	-65 M	-	10.36 %	$ 9.8 M	USA
AlloVir ALVR	-200 M	-	4.14 %	$ 49.1 M	USA
Catalyst Pharmaceuticals CPRX	258 M	$ 23.77	2.99 %	$ 2.91 B	USA
Alpine Immune Sciences ALPN	-57.6 M	-	-	$ 2.17 B	USA
Corbus Pharmaceuticals Holdings CRBP	-44.4 M	$ 8.41	-1.87 %	$ 36.4 M	USA
Cardiff Oncology CRDF	-48.6 M	$ 1.94	0.01 %	$ 130 M	USA
Curis CRIS	-44.3 M	$ 1.1	-3.51 %	$ 6.94 M	USA
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
CorMedix CRMD	-48.9 M	$ 7.16	0.42 %	$ 364 M	USA
Ampio Pharmaceuticals AMPE	122 K	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	-124 M	-	-	$ 10.1 M	USA
Champions Oncology CSBR	6.15 M	$ 6.14	3.89 %	$ 83.9 M	USA
Aravive ARAV	-70 M	-	-13.39 %	$ 1.45 M	USA
Aptose Biosciences APTO	32 K	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	-62.4 M	-	-39.0 %	$ 4.57 M	USA
Citius Pharmaceuticals CTXR	-42 M	$ 0.72	-2.34 %	$ 4.84 M	USA
Athira Pharma ATHA	-99.9 M	-	-	$ 269 M	USA
Aridis Pharmaceuticals ARDS	-29.5 M	-	17.91 %	$ 11.1 M	USA
Altimmune ALT	-103 M	$ 4.21	-2.32 %	$ 299 M	USA
CEL-SCI Corporation CVM	-24.2 M	$ 3.88	-8.92 %	$ 247 M	USA